These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: Effects of estradiol on the expression and production of IGFBP-2 by R3230AC mammary tumor cells.
    Author: Korc-Grodzicki B, Ren N, Hilf R.
    Journal: Oncol Res; 1996; 8(12):473-83. PubMed ID: 9160351.
    Abstract:
    The R3230AC mammary adenocarcinoma of the Fischer rat possesses Type I and Type II IGF receptors. The mRNAs for IGFBP-2, -3, -4, -5 and -6 have been recently identified in this tumor in vivo and in vitro. Using western blotting techniques on tumor tissue homogenates or conditioned media, we demonstrated that IGFBP-2 and, to a lesser extent, IGFBP-3 were expressed, produced, and secreted by the R3230AC tumor cells. Moreover, immunohistochemical assessment of tumor sections with anti-IGFBP-2 demonstrated that signal for IGFBP-2 was localized in the neoplastic glandular epithelium and often in the lumina of the pseudoglandular structures characteristic of this neoplasm. Expression of IGFBP-2 is regulated by the estrogen status of the host. The significant increase occurring in tumors from ovariectomized hosts was completely reversed with hormone repletion. Both mRNA expression and production of IGFBP-2 in vitro were also regulatable by the presence of estradiol-17 beta, with both processes being inhibited by its addition to the cell culture medium. Thus, the response of IGFBP-2 to estrogen showed agreement both in vivo and in vitro, whereas progesterone had no significant effect on these parameters. In the R3230AC tumor, estrogen treatment in vivo decreases tumor growth. Therefore, a relationship could exist between the action of estradiol to inhibit production of IGFBP-2 and the ability of estrogens to regulate tumor growth.
    [Abstract] [Full Text] [Related] [New Search]